Edition:
United States

Mersana Therapeutics Inc (MRSN.OQ)

MRSN.OQ on NASDAQ Stock Exchange Global Select Market

16.19USD
9:55am EST
Change (% chg)

$0.12 (+0.75%)
Prev Close
$16.07
Open
$16.17
Day's High
$16.27
Day's Low
$16.01
Volume
1,705
Avg. Vol
21,515
52-wk High
$21.01
52-wk Low
$12.65

Chart for

About

Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design... (more)

Overall

Beta: --
Market Cap(Mil.): $365.65
Shares Outstanding(Mil.): 22.75
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 192.73 16.31
EPS (TTM): -- -- --
ROI: -- -0.67 35.74
ROE: -- -3.38 17.71

BRIEF-Mersana Announces First Patient Dosed With XMT-1536 In Phase 1 Study In Patients With NaPi2b-Expressing Tumors

* MERSANA ANNOUNCES FIRST PATIENT DOSED WITH XMT-1536 IN PHASE 1 STUDY IN PATIENTS WITH NAPI2B-EXPRESSING TUMORS Source text for Eikon: Further company coverage:

Dec 12 2017

BRIEF-Mersana announces third quarter loss of $0.35 per share

* Mersana announces third quarter 2017 financial results and provides business updates

Nov 09 2017

BRIEF-Mersana announces FDA clearance of IND application for XMT-1536

* Mersana announces FDA clearance of IND application for XMT-1536, a first-in-class antibody drug conjugate targeting NaPi2b

Oct 30 2017

BRIEF-Mersana Therapeutics increases size of board and appoints Lawrence Alleva as class III director‍​

* Mersana Therapeutics Inc - Increased size of the board from six to seven directors and appointed Lawrence M. Alleva to serve as a class III director‍​ Source text: (http://bit.ly/2j4r2t3) Further company coverage:

Sep 06 2017

Earnings vs. Estimates